181 related articles for article (PubMed ID: 37802982)
21. Homer1 mediates CaSR-dependent activation of mTOR complex 2 and initiates a novel pathway for AKT-dependent β-catenin stabilization in osteoblasts.
Rybchyn MS; Islam KS; Brennan-Speranza TC; Cheng Z; Brennan SC; Chang W; Mason RS; Conigrave AD
J Biol Chem; 2019 Nov; 294(44):16337-16350. PubMed ID: 31527082
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
[TBL] [Abstract][Full Text] [Related]
23. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
[TBL] [Abstract][Full Text] [Related]
24. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
[TBL] [Abstract][Full Text] [Related]
25. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
26. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Sontakke P; Carretta M; Jaques J; Brouwers-Vos AZ; Lubbers-Aalders L; Yuan H; de Bruijn JD; Martens AC; Vellenga E; Groen RW; Schuringa JJ
Leukemia; 2016 Oct; 30(10):2064-2073. PubMed ID: 27125308
[TBL] [Abstract][Full Text] [Related]
27. HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML.
Li Z; Wang F; Tian X; Long J; Ling B; Zhang W; Xu J; Liang A
J Exp Clin Cancer Res; 2021 Jun; 40(1):210. PubMed ID: 34167558
[TBL] [Abstract][Full Text] [Related]
28. C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
Pun CC; Lee KK; Chui YL
Leuk Lymphoma; 2019 Dec; 60(12):3011-3019. PubMed ID: 31111759
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.
Somervaille TC; Cleary ML
Cancer Cell; 2006 Oct; 10(4):257-68. PubMed ID: 17045204
[TBL] [Abstract][Full Text] [Related]
30. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.
Ramakrishnan R; Peña-Martínez P; Agarwal P; Rodriguez-Zabala M; Chapellier M; Högberg C; Eriksson M; Yudovich D; Shah M; Ehinger M; Nilsson B; Larsson J; Hagström-Andersson A; Ebert BL; Bhatia R; Järås M
Cell Rep; 2020 May; 31(8):107684. PubMed ID: 32460032
[TBL] [Abstract][Full Text] [Related]
32. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
33. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
Chen L; Chen W; Mysliwski M; Serio J; Ropa J; Abulwerdi FA; Chan RJ; Patel JP; Tallman MS; Paietta E; Melnick A; Levine RL; Abdel-Wahab O; Nikolovska-Coleska Z; Muntean AG
Leukemia; 2015 Jun; 29(6):1290-300. PubMed ID: 25650089
[TBL] [Abstract][Full Text] [Related]
34. Differential niche and Wnt requirements during acute myeloid leukemia progression.
Lane SW; Wang YJ; Lo Celso C; Ragu C; Bullinger L; Sykes SM; Ferraro F; Shterental S; Lin CP; Gilliland DG; Scadden DT; Armstrong SA; Williams DA
Blood; 2011 Sep; 118(10):2849-56. PubMed ID: 21765021
[TBL] [Abstract][Full Text] [Related]
35. Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller J
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
[TBL] [Abstract][Full Text] [Related]
36. MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells.
Pession A; Martino V; Tonelli R; Beltramini C; Locatelli F; Biserni G; Franzoni M; Freccero F; Montemurro L; Pattacini L; Paolucci G
Oncogene; 2003 Nov; 22(54):8671-6. PubMed ID: 14647461
[TBL] [Abstract][Full Text] [Related]
37. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
38. Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D acute myeloid leukaemia model.
Xu H; Muise ES; Javaid S; Chen L; Cristescu R; Mansueto MS; Follmer N; Cho J; Kerr K; Altura R; Machacek M; Nicholson B; Addona G; Kariv I; Chen H
J Cell Mol Med; 2019 Oct; 23(10):7063-7077. PubMed ID: 31449347
[TBL] [Abstract][Full Text] [Related]
39. Twist family BHLH transcription factor 1 is required for the maintenance of leukemia stem cell in MLL-AF9
Wang N; Yin J; You N; Zhu W; Guo N; Liu X; Zhang P; Huang W; Xie Y; Ren Q; Ma X
Haematologica; 2024 Jan; 109(1):84-97. PubMed ID: 37767575
[TBL] [Abstract][Full Text] [Related]
40. Hes1 suppresses acute myeloid leukemia development through FLT3 repression.
Kato T; Sakata-Yanagimoto M; Nishikii H; Ueno M; Miyake Y; Yokoyama Y; Asabe Y; Kamada Y; Muto H; Obara N; Suzukawa K; Hasegawa Y; Kitabayashi I; Uchida K; Hirao A; Yagita H; Kageyama R; Chiba S
Leukemia; 2015 Mar; 29(3):576-85. PubMed ID: 25234168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
